MedPath

Clinical study of Shugan Jianpi Huazhi Decoction combined with Tongluo Yanggan application in the treatment of non-alcoholic fatty liver disease

Phase 1
Recruiting
Conditions
non-alcoholic fatty liver disease
Registration Number
ITMCTR2022000098
Lead Sponsor
Guang'anmen Hospital, China Academy of Chinese Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

1. Meet the diagnostic criteria of non-alcoholic fatty liver disease;
2. Meet the diagnostic criteria of Tanzhuo Neizu;
3. Between the ages of 18 and 65, regardless of gender;
4. Willing to participate in the research and sign the informed consent.

Exclusion Criteria

1. Patients with hepatitis B, C and other liver diseases;
2. Patients with alcoholic liver disease, autoimmune liver disease, drug liver disease, toxic hepatitis, hepatic malignant tumor, occult hepatitis, liver disease of unknown cause;
3. Pregnant or lactation women, allergic constitution;
4. Patients with mental abnormalities who cannot cooperate with this study;
5. Patients complicated with serious diseases of the heart, brain, lung, kidney, hematopoietic and immune systems;
6. Other conditions considered unsuitable for inclusion by the researcher.

Study & Design

Study Type
Interventional study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.